OTCM
NDTP
Market cap9mUSD
Jul 28, Last price
0.06USD
Jan 2017
60,900.00%
IPO
-88.91%
Name
NDT Pharmaceuticals Inc
Chart & Performance
Profile
NDT Pharmaceuticals Inc., a biotechnology company, focuses on developing various therapies for severe neurological disorders associated with traumatic brain Injury. The company is based in Vienna, Virginia.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | (168) | |||||||
Tax Rate | ||||||||
NOPAT | 168 | |||||||
Net income | (79) | |||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | (143) | |||||||
Cash flow | ||||||||
Cash from operating activities | (18) | |||||||
CAPEX | 3 | |||||||
Cash from investing activities | ||||||||
Cash from financing activities | 18 | |||||||
FCF | 209 | |||||||
Balance | ||||||||
Cash | 647 | |||||||
Long term investments | 142 | |||||||
Excess cash | 143 | |||||||
Stockholders' equity | (91) | |||||||
Invested Capital | 192 | |||||||
ROIC | 87.46% | |||||||
ROCE | ||||||||
EV | ||||||||
Common stock shares outstanding | 160,004 | |||||||
Price | 0.06 | |||||||
Market cap | 9,800 | |||||||
EV | 9,657 | |||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT |